<SEC-DOCUMENT>0001415889-14-002882.txt : 20140922
<SEC-HEADER>0001415889-14-002882.hdr.sgml : 20140922
<ACCEPTANCE-DATETIME>20140922163023
ACCESSION NUMBER:		0001415889-14-002882
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140919
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140922
DATE AS OF CHANGE:		20140922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ChromaDex Corp.
		CENTRAL INDEX KEY:			0001386570
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				262940963
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53290
		FILM NUMBER:		141114305

	BUSINESS ADDRESS:	
		STREET 1:		10005 MUIRLANDS BLVD.
		STREET 2:		STE. G, FIRST FLOOR
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		949-419-0288

	MAIL ADDRESS:	
		STREET 1:		10005 MUIRLANDS BLVD.
		STREET 2:		STE. G, FIRST FLOOR
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CODY RESOURCES, INC.
		DATE OF NAME CHANGE:	20070112
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cdxc8ksept222014.htm
<TEXT>
<html>
<head>
    <title>cdxc8ksept222014.htm</title>
    <!--Licensed to: SEC Connect LLC-->
    <!--Document Created using EDGARizerAgent 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div>
<hr style="COLOR: #000000; MARGIN-TOP: -5px" noshade size="4">
<hr style="COLOR: #000000; MARGIN-TOP: -10px" noshade size="1">
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">UNITED STATES</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">&#160;SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">WASHINGTON, D.C. 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">FORM 8-K</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">CURRENT REPORT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Date of Report (Date of earliest event reported) September 19, 2014</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">CHROMADEX CORP.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Exact name of registrant as specified in its charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="32%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Delaware</font></div>
</td>
<td valign="top" width="23%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">000-53290</font></div>
</td>
<td valign="top" width="25%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">26-2940963</font></div>
</td>
</tr><tr>
<td valign="top" width="32%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(State or other jurisdiction of incorporation)</font></div>
</td>
<td valign="top" width="23%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(Commission File Number)</font></div>
</td>
<td valign="top" width="25%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">10005 Muirlands Boulevard, Suite G, Irvine, California, 92618</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(Address of principal executive offices, including zip code)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">(949) 419-0288</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;(Registrant's telephone number, including area code)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Copies to:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Harvey Kesner, Esq.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">61 Broadway, 32<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">nd</font> Floor</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">New York, New York 10006</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Phone: (212) 930-9700</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="TEXT-ALIGN: justify; DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">[&#160; ]&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">[&#160; ]&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left">[&#160; ]&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left">[&#160; ]&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div>
<hr style="COLOR: #000000; MARGIN-TOP: -5px" noshade size="1">
<hr style="COLOR: #000000; MARGIN-TOP: -13px" noshade size="4">
</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">ITEM 1.01&#160; </font><font style="FONT-WEIGHT: bold; DISPLAY: inline">ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">On September 19, 2014, ChromaDex, Inc. (&#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">ChromaDex</font>&#8221;), a California corporation and wholly owned subsidiary of ChromaDex Corporation, a Delaware corporation, the registrant (the &#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">Company</font>&#8221;), entered into a First Amendment to the License Agreement (the &#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">First Amendment</font>&#8221;) with The Regents of the University of California, a California Corporation (&#8220;<font style="FONT-WEIGHT: bold; DISPLAY: inline">UC</font>&#8221;). The First Amendment amends the Exclusive License Agreement (&#8220;the <font style="FONT-WEIGHT: bold; DISPLAY: inline">Agreement</font>&#8221;) dated September 8, 2011, by and between ChromaDex and UC which was filed as Exhibit 10.2 to the Company&#8217;s Form 10-Q filed with the Commission on November 10, 2011.&#160;&#160;The Company sought confidential treatment for certain terms of the Agreement at the time of filing such Quarterly Report.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Under the terms of the First Amendment, UC granted to ChromaDex a worldwide, exclusive, sublicensable right and license to use certain additional patent rights relating to the use of the compound known as Pterostilbene in a specified field of use.&#160;&#160;Pterostilbene is a compound found in blueberries, grapes and other small fruits, as well as the bark of some trees.&#160;&#160;The Agreement terminates on the earliest of (i) the expiration date or abandonment of the last valid claim of the patent rights licensed under the Agreement, (ii) failure by ChromaDex to meet certain pre-development milestones or an uncured default by ChromaDex under the Agreement or (iii) upon prior written notice given by ChromaDex.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">As consideration for the additional licenses granted, ChromaDex will make additional cash payments to UC, including certain annual license maintenance fees, earned royalties on net sales of additional licensed products subject to a certain minimum amount, payments upon the completion of certain strategic milestones, as well as other consideration associated with sublicensing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">The foregoing is a summary of the material terms of the First Amendment and does not purport to be complete. You should read the complete First Amendment, which shall be attached as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 27, 2014 and, when filed, such First Amendment shall be incorporated by reference herein. The Company will seek confidential treatment for certain terms of the First Amendment at the time of filing such Quarterly Report.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">ITEM 7.01&#160; REGULATION FD DISCLOSURE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">On September 22, 2014, the Company issued a press release announcing the entry into the First Amendment.&#160;&#160;A copy of the press release is appended hereto as <font style="TEXT-DECORATION: underline; DISPLAY: inline">Exhibit 99.1</font> and is incorporated herein by reference.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">The information disclosed under this Item 7.01, including <font style="TEXT-DECORATION: underline; DISPLAY: inline">Exhibit 99.1</font> hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act, except as expressly set forth in such filing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">ITEM 9.01&#160; FINANCIAL STATEMENTS AND EXHIBITS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="TEXT-DECORATION: underline; DISPLAY: inline">Exhibits</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0.8pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Exhibit No.</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="88%" style="BORDER-BOTTOM: black 2px solid">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0.8pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="11%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td align="left" valign="top" width="88%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="11%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0.8pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">99.1</font></div>
</td>
<td valign="top" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">&#160; </font></td>
<td valign="top" width="88%">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0.8pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; DISPLAY: inline">Press Release</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font></div>

<div style="TEXT-ALIGN: justify; DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Dated: September 22, 2014</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160; CHROMADEX CORP.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;</font><br>
&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-STYLE: italic; TEXT-DECORATION: underline; DISPLAY: inline">/s/ Frank L. Jaksch Jr.</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name:&#160;&#160;&#160; Frank L. Jaksch Jr.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title:&#160;&#160;&#160;&#160;&#160; Chief Executive Officer</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!--Licensed to: SEC Connect LLC-->
    <!--Document Created using EDGARizerAgent 5.5.0.0-->
    <!--Copyright 1995 - 2014 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Exhibit 99.1</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="right">&#160;</div>

<div style="TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt"><img src="logo.jpg" alt=""></div>

<div style="TEXT-ALIGN: center; DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">University of California Irvine Completes Pterostilbene Study For</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Prevention of Skin Damage from UV Exposure</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline"><font style="FONT-STYLE: italic; DISPLAY: inline">&#8211;</font><font style="FONT-STYLE: italic; DISPLAY: inline">ChromaDex Licensed Exclusive Rights to Several Patent Applications for Use of Pterostilbene in Topical Skin Care Applications &#8211;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">IRVINE, Calif. &#8211; September 22, 2014 &#8211; </font><font style="TEXT-DECORATION: underline; DISPLAY: inline">ChromaDex Corp. </font>(OTCQB: <font style="FONT-WEIGHT: bold; DISPLAY: inline">CDXC</font>), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the completion of an animal skincare study of pterostilbene by researchers at The University of California Irvine (UCI).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">The study demonstrating that topical application of pterostilbene onto mouse skin, prior to UV exposure, prevented several types of UV-mediated damage.&#160;&#160;Specifically, pterostilbene prevented UV-mediated DNA damage, reddening of the skin, hyperplasia and loss of barrier function. Also of note, a comparative study demonstrated pterostilbene was superior to resveratrol for all endpoints of the study.&#160;&#160;It is planned that detailed results of the study will be forthcoming in an appropriate scientific venue or publication.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">ChromaDex licensed from UCI exclusive rights to several patent applications for the use of pterostilbene in topical skin care applications, including the use of pterostilbene in the prevention of UV skin damage.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">ChromaDex's branded nature identical pterostilbene, <font style="TEXT-DECORATION: underline; DISPLAY: inline">pTeroPure</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; TEXT-DECORATION: underline; DISPLAY: inline">&#174;</font>, is an anti-oxidant found in berries and nuts.&#160;&#160;It was named the <font style="TEXT-DECORATION: underline; DISPLAY: inline">2010 North American Most Promising Ingredient of the Year</font> by the independent research company Frost &amp; Sullivan. &#160;Pterostilbene belongs to a group of compounds called stilbenoids which are produced by plants as part of their natural defense systems.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">The study&#8217;s lead researcher, Dr. Frank Meyskens, Professor of Medicine, Biological Chemistry, Public Health and Epidemiology at UCI, stated, "Skin cancer has the highest incidence rate in humans of any cancer and remains a huge public health issue. The robust prevention of UV-mediated damage by pterostilbene observed in our study was remarkable. We are pleased to be working with ChromaDex on continuing this area of research and translating our findings into practical uses with potentially extraordinary benefits to human health.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">A short video of Dr. Meyskens speaking about pterostilbene research at UCI can be viewed at: <font style="TEXT-DECORATION: underline; DISPLAY: inline">http://investors.chromadex.com/phoenix.zhtml?c=212121&amp;p=irol-investorKit</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Frank Jaksch, CEO and Founder of ChromaDex, stated, "The use of pterostilbene to protect the skin from UV damage is an exciting area of research and has significant potential in commercial applications in both skin care and UV protection.&#160;&#160;We are pleased to continue expanding the intellectual property rights regarding pterostilbene as well as support the research efforts of our partners at UCI.&#8221;</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">About the University of California, Irvine:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Located in coastal Orange County, near a thriving high-tech hub in one of the nation&#8217;s safest cities, UC Irvine was founded in 1965. One of only 62 members of the Association of American Universities, it&#8217;s ranked first among U.S. universities under 50 years old by the London-based <font style="FONT-STYLE: italic; DISPLAY: inline">Times Higher Education</font>. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. UC Irvine has more than 28,000 students and offers 192 degree programs. It&#8217;s Orange County&#8217;s second-largest employer, contributing $4.3 billion annually to the local economy. The Office of Technology Alliances (OTA) at UCI manages over 900 active university inventions and has licensed founding technologies to more than 50 startup companies.&#160;&#160;OTA exists to foster faculty/industry alliances and commercialization of UC Irvine technology for the broad public benefit. To learn more about OTA at UCI, visit <font style="TEXT-DECORATION: underline; DISPLAY: inline">www.ota.uci.edu</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="FONT-WEIGHT: bold; DISPLAY: inline">About ChromaDex:</font></font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font> pterostilbene; ProC3G<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font>, a natural black rice containing cyanidin-3-glucoside; PURENERGY<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font>, a caffeine-pTeroPure<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; DISPLAY: inline">&#174;</font> cocrystal; and NIAGEN&#8482;, its recently launched branded nicotinamide riboside, a potent NAD+ booster and novel next-generation B vitamin. To learn more about ChromaDex, visit <font style="TEXT-DECORATION: underline; DISPLAY: inline">www.chromadex.com</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">Forward-Looking Statements:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">This release contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221;, &#8220;probable&#8221;, &#8220;believes&#8221;, &#8220;seeks&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221; or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex&#8217;s business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex&#8217;s Annual Report on Form 10-K for the fiscal year ended December 28, 2013, ChromaDex&#8217;s Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC&#8217;s website at <font style="TEXT-DECORATION: underline; DISPLAY: inline">www.sec.gov</font>. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="justify">&#160;</div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">ChromaDex Media Inquiries:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Beckerman PR</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">
<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Jerry Schranz</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">201-465-8020</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">jschranz@beckermanpr.com</font></font></div>
</div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold; DISPLAY: inline">ChromaDex Company Contact:</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">Laura Kelly, Executive Assistant</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline">949-419-0288</font></div>

<div style="MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt" align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">laurak@chromadex.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="1" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="100%" style="BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: justify; BORDER-LEFT: black 1pt solid"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-WEIGHT: bold; DISPLAY: inline">Statements in this press release have not been evaluated by the Food and Drug Administration.&#160;&#160;Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.</font></font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center; MARGIN-LEFT: 0pt; DISPLAY: block; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; DISPLAY: inline"><font style="TEXT-DECORATION: underline; DISPLAY: inline">##END##</font></font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!H17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````2````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8S+C4N,3``_]L`0P`!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``$0@`
M+0$#`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*
M"__$`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!
M`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#
M`0`"$0,1`#\`_OXKR+XU_'SX*_LX^![_`.)'QX^*7@CX3>!]-5OM'B/QQK]A
MH5E)*JEQ:6"W<R7.JZC(H/D:9I<%YJ%P?E@M9&XKY$_X*@_\%%OAK_P3-_9=
M\0_'GQK:1^)O%VHW0\)?"#X;QW:VE[\0/B'J%M-+I^GO(,SVOA_288I-7\4:
MK'&?L&E6[11G[=>V$<G^?U^S9\-/VU?^#B?]OE++XX?%3Q#=>%-%5_&7Q1\3
M6ZS+X%^!WPL.I+''X5^&'A1G;1=+UO7IBNA>&(I(Y;_4+O[5K^N75W%I]Y+&
M%QA=.3TBMWW\D?V)Z=_P<&?!SX^?$R\^#?\`P3Q_9A_:-_;M\=6$FS4-9\$Z
M#9?#7X5Z-`\ABAU?7/B'X^>VM=&T?(,AN=:TS2Y)D799Q7$SJA_3GX$77[>7
MBS6;;Q3^T/I7[/OPB\+3QR-_PJ;X?7?BCXE>+[,-$WD)K'Q(OF\/^'I;E)&0
MW$>C>');;<DB0W,D921O0_V6OV3?@%^QC\(_#WP2_9T^'FC?#[P-H%K`DB6$
M$<FM^)-3CB6.Y\1^+]==%U#Q)XCU%P\U[JFHRR.6D,%LEK916]K%]'#_`#]/
M\_Y[T";71??J_/R_`^)_B-XN_;?^%]UJ&N^%?AC\+?VC_",;33IX7\->(KOX
M5_$NVM8RS)!8MXE;6/".NW3+A1')?:.7;.T\A3\S^`?^"RO[+6H>-)_A=\=M
M*^)7[*?Q0L;@6>I>&/C9X6N-+TZSNV($41\1Z>+NT$,K',>H7=M9:8\6R9;U
MH7#U^N%?#G[</[!7P7_;C^'%YX8\=Z3:Z/X]TRSN6^'_`,4=.LX5\2^$M5,9
M:W2:X4+)J_ARXG"KJF@7CO;3P-+):FTO?+NT\;&X?-:,)5LKQ:JU(WE]1Q\8
MU*%5;N%.O%4\11G+51=2K5I7LG&$;R7ZMPAGGAKF>*P^4^)'#%7`8'$N&'?&
M/!F)Q&7YQE<I6A#%XW(\0\?D.:X2D^66(HX/+LNQ[I\]6%?$UE&C4^R]`\0Z
M#XKT?3_$/A?6])\1Z!JMNEWIFM:'J%IJNE:C:R#,=Q9:A8RSVEU"X^[)#*ZG
MUK8S7\&7P"_:L_:H_P""3'[1OBKX2>)I-0U;PGX1\5G2/B=\'=0OKF?PMX@T
MR1TEA\6^!I+DNNB:EJ>DS0ZQH6L6*I:ZE#/%;:M!<PLS)_<%\'OBSX(^.OPQ
M\$?%[X<:LFM>"O'N@VFOZ%?`;)1!<JRSV5Y#N)MM1TR[CN-.U*U8LUM?6EQ`
MS$Q[CSY%Q!0SF-:E*E+"8_"R<,5@ZCO*#4N1SA*T7*"G[LDXQG3DU&:]Z$I>
M[XT>!F<^$E7*LSHYEA^)^">):<*_#?%>`I\E#%0JT(XNEAL92C.M##8NIA)Q
MQ.'=.O6PV.PW-7PU5RI8FAAO2Z*^<OVL_P!J?X0_L7?`#XA_M'_''7'T/X>_
M#K2A>WWV2);G6-;U.[GCL=$\,^'K!GC.HZ_X@U2>VTW2[,.BO-/YL\D-K#//
M'_%QK7_!T%_P4@_:-^(>M:'^Q%^Q-H&HZ#I]Q)-8:!:^$?B%\;/'RZ.\S+9W
M7BK_`(1$6&D:;=31;&=+*W6W0AE267:7/T)^&1A*6R_3^MS^]3-%?Q=_LS_\
M%=_^"]_Q$_:+^!/@#XM?L':EX3^%WC7XM>!/"_Q$\42_LT?%W1(_#O@K6O$%
ME8>)-:?6=0O#8:4NG:7-<W)U"]5K2T\OSILQ*P/TA^W#_P`%I_VN/V=O^"S/
MPI_8#\!>'_A+>?!?QOXZ_9I\.:GJ&N>'-8O/&J6'Q<U6QL?$YM-3M]9M[-+F
M&*YD.E,U@ZP.%,J3#@@_9RO;2]K[WLO/^O3H?U:4444$!1110`4444`%%%%`
M!1129'^?\_Y'/2@!:***`"BOPB_X+X?\%)/C[_P3._9[^"WQ2_9]TKP!JWB'
MX@?&=O`.NP_$'2-0UC3HM$'@GQ'XA$EA#IVHZ;)%>_;M)ME,LDLJ?9VE01[F
M5E_G[\$_\%Z/^"^WQ+\(:1\0/AS^P_I_CWP+XAM9KW0?&/@[]FSXM^(O#6LV
MMO/+:S7&E:QI>J7-C?0Q7,$]O));S2*LT,D>0R,`%J#DKJUM=VEM_P`.?WPT
M5_#O^S/_`,'6WQJ\$_&+3OA5_P`%%?V8M)\!Z`=6L]&\6^,/`^F^+/"?CCX=
M/>RQ1'6?$_PV\8F:2_T:Q5OM%Y!IUS9ZFEJ9+B$7?E"W;^VOPSXCT+QCX=T'
MQ=X7U:RU[PSXHT72_$7A[6]-E$]AK&AZW90ZEI6J6,R`+-:7]C<P75M(,[XI
M5<8W8H%*,HVNM_-/\K]S=HHHS]?R-!(445^*OCSX]?M-:=^TU>V6E>,-<M(;
M'QN_AVQ^$_\`9=@^F7LHU?4X/#/A6'PPNER>(]:L?&WA2WL/$EQ\4X-4BT#0
MGN[LS36GV:UMJ!I-['[54444"/\`.6_X.N/VCM<^)_[=W@;X"[K^T\(?LZ_#
M>%[;3I6E6RU'Q=\1?L6MZKXAAA<>4TZZ/#INC"9`<PVK(6W$BOWI_P"#4+X&
M^&_`?_!.KQ!\:;:TMV\8?'SXT>-;K7-2VQM=#P_\.+G_`(0OPQI!G`\P6MK)
M;:UJ:VQ;:EUK-W+RTA-?&O\`P=B?\$_?$?BWP_\`#/\`X*`?#+PY/J</PZTN
M7X:_M`V^DV9DN;/PI?WT=SX,^(6HI`&FFLM&U*2;PWK%ZX$>GV5]I+RGRO,>
M/AO^#4O_`(*/^!?#FA^+O^"=7Q4\06/AW7M5\6ZO\2_V=+[5;J.ULO%%QX@A
MAG\=?#FVN)B(_P#A(8K^U_X2G0+0OOU:WOM9M+8-=65M#=!NW>BK=/B7];=_
M^"?W!T4?Y_S_`)^M%!@%%%12S1P1RS3.D,,*/++-*ZQQ111J7DDDD8A(XT52
MSLY"J@+$@4`KO1*[>B2ZG\EO_!QC\*=$T;XH_L__`!FTZW@M]9\<>%_$W@?Q
M*\:*LFHMX/NM/U+P_>S!<>9-#9:YJ-B\KAG^SPV4.=L*`?6?_!NK\3];\1?L
M^_&OX5ZG/<7&F_#+XE:;J7APREI%M;+QWHKZA?V,,C96.&/4=+EN8K=2%5[N
M:0*#(Y/Y'_\`!:+]L_PU^U;^TAI?A/X::DNN?##X%6.I>$='UNRS-9^+/&FL
M7UNWBS6-*,>X7NG0S6&G:!H\\0;[:;*[NK<M#?1"OZ*_^"-G[)&N?LK?LEV%
MQXZTZ32?B7\:-7'Q*\7:5<H8[S0M.N;&&S\(^'[^-@K)?V&B*+R^B<"2UN]3
MGLIE6:V<5^995;&<=8_%Y>[X.E"K]9J0UIU&Z$*,DFM'[3%)U(ZOG]G*I%-+
M3_17Q+53A3Z&'!'"_&\94N*\SQ&6RR#+L7IF&#IT\ZQ6<4)3HU+5J2R_AFO'
M`XA.*>$ECL/@*RA.<4_Q;_X/!OB/KNC?LX?L@_"RRN[B'0/'_P`9_&_BKQ!:
MQM(L-[<_#SPCIT6A)/MPLJP2>,M1E2*0$"01RX#1JR_IM_P;B_!GP-\+/^"4
M/[.WB3POHNF6?B/XSV?B+XG^/]=M[2!=5\0:]JOB;6;*R75KY$%Q=QZ'H]E9
M:1IEO-(T5C:6YC@1&EG:3Y1_X.L/V5_&7QQ_83\"_&KP/H]]K][^RU\2;GQ?
MXMTW3K>6ZN[;X;>--(CT#Q5XA2"!))I(/#^H6'AN\U'8A%MI+ZAJ,I6"RE<?
M"/\`P0-_X+N_L??L]_L>^%OV1_VO?'EY\(O$'PEU;Q'%\/\`QU?>'M?\0>#/
M%O@;Q!K%WXAT[3Y+[POINL7>C:YX?NM2O=+>+4+**PO=/CL+FWOC.\T"_II_
MG?9NFK*]I.Z7GHM#^W+GU_3_`#]?T]Z_S>/^"[OA7X@^._\`@O\`Z!X)^$OB
MA?`_Q5\7S?LH^&OAKXTDO+G3D\)>.M:6"P\+^(VU"UAN;JQ&CZQ/:7S75M;7
M$\'DF2*)V4(?[*O`'_!</_@EA\4O'7@[X:>`OVNO!OB+QOX_\2Z-X/\`"&@V
MWAGXB07&M>(_$-]#INCZ9!/>^#[:SBEO;Z>&W22YN(8$9P9944%A_)C_`,%7
MO^5G7]GG@$?\+8_89SS_`-3#I/J/;IG\CU`IJ2;T:]V^J\XN^ITO[;/[.W_!
MP]_P3B^"VH?M4>-O^"A_B#QYX!\$:OH-IXJD\$_$S6-;U'P^OB#6+31-+U#4
M?#/C+P39:=J^B7&K7UEI]\(9+F:W^UQM):FV\V:+]W/V5O\`@HK\8OVR_P#@
MA#\:_P!JC7]7_P"$2_:%\`_"+XZ>$O$7B_P8HT1V\>?#C1;MM,\<:)!&'CT6
M]U;3Y](UF6TMPUO9:E-<QVJI;+$B^T?\'&V?^'/W[5N"?N?"OV_YJ]X'_P`<
M_ASWK\>?^"/.?^(;7]N+UW?M7].__%!:%TP>N./K^=`_BAS-*ZFEHDM++0_)
MC]@1_P#@NE_P44^#7QT^,'[/W_!0#XDE/V>CI,'B#PIXQ^*^MZ1X@\4WFH^'
M-1\30P>&);?PYJ6DO<O::5<P1+J]W80S7LD,+3I$7E3]>_\`@@G_`,%L?C9\
M0?@;^W,?VW_B%??%G1_V.?A39_';3_B)J,&E1^.[KPNY\0Z=JO@?5[G2[>TM
M=;U!]6T.UB\.WT]JMZ9M2:RN)KE5B84_^#..WAN_@+^W':74,<]M<_$WX/6]
MQ;RH)(IH)_`/B6.:&1&&UTDC8HZL"&4D$$$Y_;#]OO\`X)U?!:Q_X)Z?MS>`
MOV1_V>_AO\./B;\4_@-KMD(OAIX.TGP[K/C6;PE=IXUTWPS/)I=M#-J#ZA>:
M=<VUA:R%E:]U``#,AR!)QYG%I)<RLTDK+W;IV\E_2T/Y>/V?/BQ_P6T_X+]?
M%OXP^-/@U^T]<_LG?`?X<:M:P+I?ACQ%KW@[P5X0EUO[5=^&/!EC)X/MU\7>
M/?%ZZ-`M]XAUC4]5M[&*-HY]EL+RQLY.O^%'_!0K_@I[_P`$6?\`@H!X#_9,
M_P""AOQ=U']H7X#^/;SPJ+S6O$&L3>+E@\#>,]8E\/Z9\4_AQXSU:TL?$]L?
M#NMQ7*>*_"_B)[J,PZ?J=O&$ECL;V7J?^#6G_@H?^RM^S;\-OVB/V:_VB?BG
MX0^"/B[Q/\3['XH>#]<^(^IVGA3P[XCL_P#A%=*\)Z]X<D\0ZJUMIUAXC\/W
MOA^.=M*U2XM)[BVU!ULUEEL[F-/D+_@OC^T+\./^"H'_``4S_9M^"O[&&NVG
MQGFT3PUX8^"5CXN\$B35=%\2^//&'CN^UC5$\.:C;QE-6T+P=I=U;76J:]:F
M32X9(-7EBN9+6T^T2!=ES2ARKDY=^7R3O=>9^EG_``=(_MF?M4?LV?'#]CW3
M/V;OVB/B?\'M"\<?"CXA:IKUC\/O$<FC:=X@OK?Q?X;M=*U2_BCAD^T3VUI>
M2PP3%ALMYW4+SFO@7]M_X1_\%UOV#/V6O"_[6OQ6_P""E7BKQ'\/_%NO>`M`
MT[1O!7Q0\7W7B:&[^(6B:CKND/<0ZKX5T[3O(MK73IH[UHKZ1A,R&%98R67T
M_P#X.X-)FT#XR?\`!/G09YC<3Z-\!_&FD37&2QN)=.\7>"[.28L023(T+2%C
MUSZGC]2?^#DG_E"/\#.O_)3?V7/7/_)-_%??G^M!$'94U9>\VG=7=KJUOG<_
M%OX;_#+_`(+[_$;]@5?^"CGP[_X*$^-]:^&%CX1\3_$*7P2_Q6UN'XD0^'/!
M>H:E8Z[<P:??>%9_#-Y?6BZ5>7\>FS:LGVJTC`1VG9('_HU_X-R/^"E'QG_X
M*$_LN?$NP_:(U:#Q;\6_V??'&A^%;_X@Q6-GIEUXX\)>+]%N=8\)ZEKMC810
M6(\2V3:7K&GZK>V5M:P:A'#8736\=U)<E_%_^">7_*L7JW7_`)-;_:4]?^?S
MQYGTXSGICCI7YB_\&MGCOQ/\+OV)_P#@K'\2_!.G_P!J^,OA[X.\(^-?"NFM
M!]I6^\1>%_A#\5M;T2W>U`S=12:E90*]NH+S1EH5!=QD&_?C-V2:DDK*V[2_
MR/H;Q]_P2V_X.!_^$T\6ZA8_\%7_``MX<T34_$VNZEH.DZC\:/'6GS:;H6H:
MK=76D6+6\G@<+%]EL)8;<1QL\:F/$<CKAJ_.[XG_`+9W_!9;_@BG^U=\%[/]
MI_\`:MM?VG?AEXY-KX@U+PX?','Q(\!>-/`T&O6^B^+;..]U+0M(\3^#?&.D
M02O<Z=<1B.)9#!,O]H6SS1K^:G[$OPX^#G_!1SXE?&KQO_P40_X*9ZG^S5XF
M/]F^)M)UWXB:O/K%]\0]9\1WE]<ZXEAJ'B?5K;P[I.G^'&2&WCT*S\B=$N(5
MLK2&RMW`\X_X*7?LH?LE?LLZ]\*M-_92_;CT;]MC3/&&DZ[?>,=7TB?09U\!
M7NFW]G!INGW!T#4+^.-M:@FFN$2Z:.8FV+!3&RF@M+7E=NUO9VOHNNW3>_16
MZ']8W_!VMX@T_P`6?L&?L?\`BK26=M*\3?M`Z9X@TQI5V2-I^L_![Q?J-DTB
M`D)(UO<Q%E!.UB0"<9K]>/\`@@62?^"1'[%&2?E^'GB`#/.!_P`+"\8\#T&2
M2`/ZU^(O_!S]_P`HM_\`@GD.F?B!\.<>@Q^SWKI_D#BOH/\`X(]?\%C_`/@F
MM^S?_P`$VOV6?@K\:_VI/"?@3XG^`O!>LZ;XN\):AX=\>7MYHU]<^-/$VIPV
M\USI/A74-/G:2QOK2<-;7<RXF520X8`,;/V:LOM/[[?Y)'RG_P`'@GP%\#Q>
M%_V2OVD[#2;"S^(-WXJ\8?!_Q1JL%O##=^(_"<FB0^)-`MM1DC19+Q]"U*WO
M_L<MPTLD%MJ$UM"T<3;3WWPB_P""NGBG]A;_`(-T?V4_BYH]I8^*?C]XB;7?
MV=?@Q%XF$M_I<.H>%M>\2PMXT\06WFI)J>E>"O"^GP^5IPECCO\`4&T/3YV6
MTGN&'Y(?\'%7_!6CX.?\%&?&_P`#?@[^RQ=:YXR^$GP:O_$.N3^,+C0=4T23
MXA_$KQ?'::#I^F^%M#U."VURYTO3--MQ!:7%_IME=7^J:HR6EJ8HUFF^I?\`
M@K+_`,$^_BO\"/\`@@O_`,$V(;SPWJ)U3]FS5;KQ#\>=-M[>9[CPK=_'S3?[
M5GU;6K=5+6<'AW7AI?AC5I)`%L-1U&)9F1#*ZA?V::FOM:)V7N_U;Y/O8C_9
M@^!G_!P;_P`%`/A#X=_:HLO^"E>G?"?PE\4?M^K>#=%\6_%L^$-3O]$AU&ZL
M5U.U\&^"/!]UIOAS1KFXMISH]I=W(U![)8IYK>..:-I/WY_9#_8-_P""@Z_L
M)_M(?`7]IK]OK7_%G[0/CGQ9/K_P5_:#^%'Q(US7-6^&,UAH5F=`TZ[U._T;
M2YVT>;7[9SX@T)+6>*^T:]N5BE2Z:%X_X]/V*?V!/^"77[1GP!\'>/?C%_P5
MK?\`9E^+<UK<6OC[X-^--%\/Z$GA76;6[GA1?#FIZ[J=E%XB\/WUH+;4+#4+
M&24A)S#=Q6US%+"/[*?^"(OP#_9$_8S_`&7OCI%^S[^V_P"&OVM/A<GQ$U'Q
MUX]^*JWWA^WT7X?S:7X2LWU/2]4OM+U&\L;2WL='L_[8N;BZGB\FW<R,HC7-
M`IZ?)Z>Y:VW7RVZW\]+?S]?L"_\`!=3]I+_@G%\0_P!KW]E7_@JAK?Q*^*7B
MWX<6?BS4_AY>^)9)M?\`%MI\7O#=GLT[X;C5T@B:7X>?%.W.GZSX8\33+)8Z
M.KR7P9[+5`(OI/\`X(-ZE_P4F_X*3_M)^.OVZ/VC_P!I;XR:)^RYX*\=:Y>>
M'OAGHNMOHG@?XB?$*ZN?M5O\//#]G':I-_PJ;X:VDMJFN6T,[1ZQJD6FZ1-)
M))_;+P?AY_P4]^+_`(\_X+5_MZ_''XD?L=?`B[\3>!/@!\']<E/B#PIHL=KX
MK\8?";X7W-U+J7Q6\:W#M$]]>ZE/=36W@+0`)-;.@1V>G6EM=7HN(8/ZN?\`
M@VI_X*+_``I_:8_9"\/?LH+HOA7X<?&_]EOPU9Z+J'@[P_:PZ1IWC[X?/<-'
MI7Q2T&Q4[IKZYNYQ9>/DS+<6_B6=-3E;[/K=MM!R24+I)2:7-:WNZ+ITOIMW
M/Z6Z***#`Q?$?AO0/%^@:UX4\5:-IGB/PSXCTN]T/7]!UJRM]2TC6='U*WDM
M-0TW4K"ZCEMKRRO;6:6"YMYXWBEB=D92":_B+_X*,?\`!K3X\\/>-=0^._\`
MP3#\606<,&L#Q79_L_\`B7Q++X8U_P`%:W:7`O[>?X-_$F:>.**&SO(UGTC1
M?$U[IUUI16."Q\07")%;+_<=1CMZY_7K05&3CM]W1^3]3^-O]B[_`(+J?MB_
ML9S:'^SM_P`%F/V8/CUX;M](\C1=&_:BM?AIKUYJ)LX%2"WN/B/I>DV,^F>+
M+5$57E\;^#KN>^O(E>YN-&U6XD:XK^JKX"?M1_L\?M1^$;3QU^SW\9/A]\6_
M#-XF[[;X-\1V&J7-E*%5I+35])24:OHFH0$[+G3M7L+*]MI`T<\$;J5KVS4M
M+TS6;*?3=8TZQU73KI#'<V&I6EO?65PAZI/:W4<L$J'NLD;#VKP[PG^RI^S7
MX"\?S?%3P)\#?AAX(^(ES%-#=^+O!WA#1_"^L7L5PA2:._GT.VL%OE=6(Q=I
M-MZK@@&@&XOI9^6S^73Y=SGOV@_VS/V;/V7M'EU/XR?%3P[X?OO)EDL/"-A.
M=?\`'.MRQ#BVT;P?HWVS7+R1VQ&)6M(K2-F!N+F!`S#^>?\`:6_:^_X*#?\`
M!3+^T?@[^QU^SY\4OAO\`-:D;3M9\7:O8S>%-9\:Z;(YB=/$_C34WT_1O"GA
MZZBS)<:!I5]<7M["7@N[^]CQ!7]*>E?L[_`G1?$>H>,-.^$7P]B\6:K</=:A
MXFF\*Z1>Z_=W#L7:675[ZVN;\MN)*XG`3/R!17L:(D:+'&JHB*$1$&U$10%5
M45<*JJH`4*`%`P,5X689;F&:*5"MF/U+!3O&I1P%-_6*U-Z.-3&59/EC)7O&
MEAXK5QE*I'?]GX(\0>!O#JI0SC*N`_\`6_B_#*%;!9QQKCXO(LIQD;2AB,#P
MIEE*/M\10J>]1Q689[B)0G"%?#T,)62<?P!_X)[?\$0_!O[/FN^'OC'^TOJ>
MA_%'XJZ)-;ZEX6\$Z5"\_P`./`NJ0[7M]1G-[#%-XN\06$@#6=S=6EKH^G3H
MLMK97,R17B_O_C!)YY_S_GZT8'\O7M_G^M+7;EN5X+*<.L-@:"HT[\TWK*I4
MG:W/4F[RG*VBOI%:148Z'QW'WB-QAXFYY/B#C'-ZN9XWD='#4E&-#`Y=A>9S
M6$R[!4E&AA:"D^:2A%U:]2];$U:U>4JLJ=_I]CJMC>Z7JEE::EIFI6MQ8:CI
MU_;0WEC?V-W"UO=V5[:7*26]U:75N\D%S;SQR13PR/'(C(Q!_#+XN_\`!MY_
MP28^+_B[5/&5U\`];^'NH:S=RWVH:9\)OB)XK\!^&Y+RX8R7-Q!X=T^]FTJP
M-Q,SS/#I]O:VR.Y$,$485%_=FBO0/B$VMG8_!+X2?\&VO_!+[X)_%/X<_&+P
M)X,^,5MXU^%GC3P[X^\)7&I?&GQ9J>G0>(O"^IV^K:3+?:;<'R+^U2\M8FGM
M)OW<\8,;_*QKZ=^-_P#P1O\`V)?VA/VQ?"W[=7Q(\._$2[_:`\':Y\-O$.B:
MII/Q(U[1_#$6I?"BZ@O?"#W'A6U/]G7$5O/;Q-?0O\M^H*3_`"L17ZH44!S/
M>[O:WR/G']K+]E;X1_MJ?`;QM^S?\=+'7=2^&'Q`_L3_`(2.S\-Z_>^&=8E_
MX1_7=-\1Z;]CUK3\7=GLU/2K.27RO]=$LD+_`"2-7@OP%_X)B_LI_LW?LC?$
M?]B/X8:)XUL_@/\`%0^-SXNTW6?'.L:UXEG_`.%@Z9;:1XC^P^*+L_VA8>;9
M6D*VGD?\><@:2+YF-?H110%W:UW:]_F?GY^P'_P3+_97_P"":?AOXB^%/V6]
M%\::-I'Q2UKP_K_BU/&?CC6/&T\^H^&=-N])TI[&?5R7L(DL[V=9H8,+.Y61
M^4%?H'^E%%`KGXD?M7?\&]W_``3(_:Z^(6L_%;QC\(M=^'GC_P`2WLVJ>*-;
M^#7B_4/A_:^)]6N9&DNM7USP_9QW7A^XU2Z9BUS>V^FVD]S+F>X:6=Y9)/=/
MV'/^".7[`W_!/?7+CQG^SY\('_X63<V4VFGXH_$'7+_QYX]L].N@!>6&C:SK
M):+0+6]`"7:Z)9V$EQ#F":62%G1OU#HH*YI6M=V['YD?MZ?\$COV-O\`@I%X
ML^''C7]I[0/'^L:Y\*]#UCP[X1D\'?$+7/!=K!INN:I8ZOJ"7UKI)\N_F>]T
M^V:*:;YXHU:-?E<UZ]^UQ_P3]_9R_;:_9U\-?LM_'?2?%FI?"7PIK'@S7='L
M?#7B_5/#&N1ZAX"TB^T3P\\^O:>?MMQ%#8:A<K=1.=MW*R2R_,BU]LT4"N]/
M)W7D?&7PK_8+_9Z^#?['4_["G@C2O%-O^S_<>#/%_@*72]1\6:EJ7B@^'O'$
MFIRZ_$/%<_\`Q,ENI7U:\-M=@^;:AHQ'_JUKSS]@?_@EU^R9_P`$V="^)WAS
M]F+P_P",M,TGXNW?AN]\:VWCCQOJWCL7LGA73]4TS28[4ZUN%G`+36;Z.[AC
M!2[,B&8'RU%?HA10%W]Y^"OQ6_X-K/\`@DU\6?''B#Q[?_!7QAX+U'Q-JEYK
M.IZ-\-OBAXK\'>%%U'4)FN+V?3_#EI<S:?I:7%S)).UKIZ6]I'(["&"./:@\
MX/\`P:R?\$DL%?\`A!?C>`<?=^._C(=/H>_?ZGM7]&-%`^:7\S^]GY]_MD?\
M$R?V5?V[O@Q\*O@+^T%HGC35?AY\&M4TG6/`]KX7\<:QX4U2VO=%\*W/@VQ;
M4=6TTBYU.-=$NYHY([C*RW!6Y;]XHK\U/^(6;_@DH<_\4-\<.?\`JN_C+TQZ
MU_1?10)2DMFU_7_`/Q]_9<_X(0_\$R/V1O'ND?%'X9?L_1:[\0?#EQ'>>&?%
M/Q2\2ZY\2;WPUJ,)#1:IH=KXCN;C2K#5(6`>WU!-/:[M9`LMK+#*JN/UB\5^
M$_#/CKPUKO@WQIH&D>*O"?B?2[S1/$7AOQ!I]MJNB:WI&H0O;WNG:GIM['-:
MWEI<PNT<L,\3HRGID`UT%%`7;W;9_/WXW_X-CO\`@D;XU\1ZEXBC^#/CWP6-
M3N9KIO#_`(#^+OC30/#%DT\K2M%IFCO>7L=C;(6*Q6\,HBB3"(H`%?1_@'_@
MB5^Q'\+OV3/BQ^Q5X!B^-7A?X%_&_P`76/C#XF:=I7QC\3VWB?Q+<64%I;-H
M<WBM,:K;^%]0CL;0:MH=M)%;ZBL(BN&:!Y89/UUHH'S2>[;V>_8^!/V$?^"9
MW[(W_!.+PGXX\)?LP>`]1T*'XCZQ;:QXTUWQ9X@O_&?BG7/L%H;+2])N==UC
M?=+H.E027)T_1HA'90S7EY<-&\UP\A^=?A7_`,$,OV!O@7^U7%^V/\%_#OQ3
M^%WQA@\9Z[XTBA\%_%?Q+I'@-9_%$D\GB/PV?!",^C/X*UDW5PMYX6=#IH27
9;;);^5;F+]A:*!<SUU>N^KU]0HHHH$?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
